EXPO

Business Context and Reporting Period

Company: Exponent, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and nine months ended September 27, 2002.
Business Overview: Exponent is a science and engineering consulting firm providing solutions to complex problems across more than 70 technical disciplines. The company operates two primary segments: Environmental and Health, and Other Scientific and Engineering.

Key Financial Metrics

Note: All figures in thousands except per share data. Operating cash flow shown for nine-month periods only.

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 7.6% in Q3 and 7.5% for the nine months ended September 27, 2002, compared to the prior year. Growth was driven by increased billable hours, higher billing rates, and the acquisition of Novigen Sciences, Inc. in May 2002.
• Profitability: Net income rose 31.1% in Q3 and 23.4% for the nine-month period. Operating margins improved due to cost controls and the cessation of goodwill amortization following the adoption of SFAS No. 142.
• Expense Management: General and administrative expenses decreased 25.1% in Q3, largely due to the reversal of a sales tax accrual and reduced goodwill amortization. Compensation expenses increased 9.1% in Q3 due to salary increases and bonus accruals related to improved profitability.
• Cash Flow: Operating cash flow turned positive, providing $6.9 million for the nine months ended September 27, 2002, compared to a use of $4.9 million in the prior year. This shift was primarily due to improved collections (accounts receivable) and lower bonus payouts in the first quarter.
• Acquisition Impact: The acquisition of Novigen Sciences, Inc. added $1.1 million in revenue for Q3 and $1.7 million for the nine-month period. Goodwill increased by approximately $1.9 million associated with this transaction.

Guidance, Outlook, and Risks

• Outlook: Management anticipates continued revenue growth from the Novigen acquisition and the new "Objective Force Warrior" agreement ($7.5 million value), expecting approximately $2 million in net revenue from this contract through the remainder of fiscal 2002 and the first half of 2003.
• Land Warrior Program: Revenues from the Land Warrior program are expected to remain at reduced levels through the remainder of 2002 as the program is in the pre-production phase.
• Liquidity: The company maintains a revolving reducing mortgage note with $26.0 million available and a $0 outstanding balance. Management believes existing resources and operating cash flows are sufficient to fund operations for the next 12 months and beyond, though future acquisitions may require additional capital.
• Risks:
  • Backlog: The company operates with a small backlog relative to revenues, making future revenue less predictable.
  • Customer Concentration: Significant revenue is derived from the transportation industry and government sector; loss of a major client could materially impact results.
  • Competition and Talent: The market is highly competitive, and the business is labor-intensive, relying on the ability to attract and retain qualified technical personnel.
  • Economic Sensitivity: Demand for services is cyclical and subject to general economic conditions.

Investor Verification Checklist

• Novigen Integration: Verify the realization of projected synergies and revenue contributions from the Novigen Sciences acquisition.
• Land Warrior Revenue: Monitor the timeline and revenue recognition for the new Objective Force Warrior agreement versus the declining Land Warrior program.
• Customer Concentration: Assess the stability of revenue streams from the transportation and government sectors.
• Goodwill Impairment: Review future annual impairment testing of the $8.6 million goodwill balance under SFAS No. 142.
• Real Estate Utilization: Evaluate the status of leasing the vacant 24,000 square feet in the Silicon Valley facility, which impacts rental income.